Trial Profile
Randomized Open-label Active-controlled Study to Assess the Safety, Tolerability, and Efficacy of Afabicin IV/Oral in the Treatment of Patients With Bone or Joint Infection Due to Staphylococcus
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Dec 2023
Price :
$35
*
At a glance
- Drugs Afabicin (Primary) ; Afabicin (Primary) ; Cefazolin; Clindamycin; Clindamycin; Linezolid; Linezolid; Vancomycin
- Indications Bone and joint infections; Staphylococcal infections
- Focus Adverse reactions
- Sponsors Debiopharm
- 03 Oct 2023 Planned number of patients changed from 96 to 111.
- 03 Oct 2023 Planned End Date changed from 12 Apr 2025 to 31 Mar 2026.
- 03 Oct 2023 Planned primary completion date changed from 12 Apr 2025 to 31 Mar 2026.